Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (171-180 of 283) with videos related to

Pageof 29
Sort By:
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Leukemia|April 15, 2022
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cellsJulie O'Neal, Julie K Ritchey, Matthew L Cooper, et al.
European Journal of Haematology|April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patientsMaurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.
British Journal of Haematology|April 14, 2016
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assaySusan J Lee, Konstantin Levitsky, Francesco Parlati, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Single-Cell Proteomics of Human Peripheral Blood Mononuclear Cells Exceeding 600 Cells per DayJames M Fulcher, Yumi Kwon, Pranav Dawar, et al.
Blood Cancer Journal|March 23, 2018
A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5Brian S White, Irena Lanc, Julie O'Neal, et al.
Blood|June 6, 2012
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaAndrzej J Jakubowiak, Dominik Dytfeld, Kent A Griffith, et al.
Research Square|November 1, 2024
<i>LINC01432</i> binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapyRicha Mishra, Prasanth Thunuguntla, Alani Perkin, et al.
Pageof 29

Showing results (171-180 of 283) with videos related to

Sort By:
Pageof 29
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Leukemia|April 15, 2022
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cellsJulie O'Neal, Julie K Ritchey, Matthew L Cooper, et al.
European Journal of Haematology|April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patientsMaurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.
British Journal of Haematology|April 14, 2016
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assaySusan J Lee, Konstantin Levitsky, Francesco Parlati, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Single-Cell Proteomics of Human Peripheral Blood Mononuclear Cells Exceeding 600 Cells per DayJames M Fulcher, Yumi Kwon, Pranav Dawar, et al.
Blood Cancer Journal|March 23, 2018
A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5Brian S White, Irena Lanc, Julie O'Neal, et al.
Blood|June 6, 2012
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaAndrzej J Jakubowiak, Dominik Dytfeld, Kent A Griffith, et al.
Research Square|November 1, 2024
<i>LINC01432</i> binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapyRicha Mishra, Prasanth Thunuguntla, Alani Perkin, et al.
Pageof 29